| When a tiny company with a game-changing medication enters late-stage FDA trials…
While showing the potential to capture $10 billion per year in sales… from zero today…
Folks with big bank accounts start to take notice.
They understand what FDA approval can mean for little-known companies developing potential “blockbuster” treatments… - Constellation Pharmaceutical’s stock shot up 1,075% after positive Phase III results…
- Cardiff Oncology saw shares rocket 1,890% after positive news from the FDA …
- And Axsome Therapeutics jumped 3,570% in a year when it saw positive FDA data …
It’s only natural these big money investors become very interested as the FDA trials roll on…
And that’s just the situation we’ve got on our hands with a tiny company Luke Lango has been following for over three years…
Take the legendary Silicon Valley investor, Peter Thiel.
He co-founded PayPal, raking in $1.2 billion… and was the first big investor to back Facebook, making over $1 billion on his stake.
Point being, Thiel has a tendency to spot early-stage tech companies with massive upside potential, well before the masses jump on board.
Thiel has purchased about 20.8% of this tiny drug company.
Big banks and institutional investors are also climbing aboard, purchasing hundreds of thousands of shares…
Including Morgan Stanley… Barclays… Wells Fargo… Bank of America… JPMorgan Chase… and Citigroup…
Click here to see why.
To your success, |
 |
| Luke Lango
Senior Investment Analyst, InvestorPlace |
| |
